Investment Thesis
Cingulate Inc. is a pre-revenue pharmaceutical company with severe operational losses (-$22.4M net income, -$17.2M operating cash flow) and negative profitability metrics across all dimensions. Despite holding $11.0M in cash, the company is burning cash rapidly with only 7-8 months of runway at current burn rates, creating significant solvency risk without achieving clinical or commercial milestones.
Strengths
- Maintains $11.0M cash position providing near-term operational runway
- Low debt burden (0.00x Debt/Equity ratio) with no long-term debt obligations
- Adequate liquidity ratio (1.16x) for immediate operational needs
Risks
- Severe cash burn of -$17.2M operating cash flow with only ~7 months cash runway remaining
- Negative revenue (-$1.4M) with complete lack of commercial traction or product sales
- Pre-revenue biotech model with high R&D expenses and no evidence of clinical success or near-term revenue catalysts
- Unsustainable financial structure with consistent quarterly operating losses and negative free cash flow
- High insider trading activity (10 Form 4 filings in 90 days) suggests potential dilution or confidence concerns
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway duration
- Clinical trial progress and FDA milestone achievements for lead candidates
- Monthly operating cash flow trend and path to cash flow breakeven
- Insider ownership changes and dilution from future financing rounds
- Revenue recognition from any commercial partnerships or licensing deals
Financial Metrics
Revenue
-1.4M
Net Income
-22.4M
EPS (Diluted)
$-4.44
Free Cash Flow
-17.4M
Total Assets
15.1M
Cash
11.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
1,464.8%
Net Margin
1,649.4%
ROE
-894.8%
ROA
-148.9%
FCF Margin
1,278.9%
Balance Sheet & Liquidity
Current Ratio
1.16x
Quick Ratio
1.16x
Debt/Equity
0.00x
Debt/Assets
83.4%
Interest Coverage
-22.12x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T10:22:10.834241 |
Data as of: 2025-12-31 |
Powered by Claude AI